INTRODUCTION

Cholesterol and cholesteryl ester movement into and out of cells mediated by lipoproteins and cell surface proteins such as Scavenger Receptor class B, type I (SR-BI) and ATP-Binding
Cassette transporter A1 (ABCA1) plays an important role in cellular and whole body lipid metabolism and can profoundly influence the risk for atherosclerosis and coronary heart disease (1-8). The pathologic consequences of naturally arising or experimentally induced disruptions in the SR-BI and ABCA1 genes clearly demonstrate that these lipid transport proteins serve physiologically important, yet dramatically distinct, purposes in HDL metabolism (1, 2).
SR-BI, a member of the CD36 superfamily of proteins, is a 509 residue glycoprotein (apparent mass of 82 kDa) containing two predicted transmembrane helices adjacent to very short N-and C-terminal cytoplasmic domains, with the bulk of the protein composing a large extracellular loop (3, 4) . Alterations in SR-BI expression can influence profoundly several physiologic processes, including biliary cholesterol secretion, female fertility, red blood cell maturation, and the development of atherosclerosis and coronary heart disease (5-7, 9-14). SR-BI tightly binds large, spherical cholesteryl ester-rich HDL particles, primarily via its major apolipoprotein, apoA-I, but lipid-free apoA-I is a poor ligand (15) . SR-BI mediates the selective uptake of HDL cholesteryl esters (16) (17) (18) (19) and other lipids (3, 20, 21) into cells, after which the lipid-depleted particles dissociate from the cells. The mechanism of selective lipid uptake differs markedly from that of the classic coated pit-mediated endocytic uptake of LDL receptors (22) .
The binding of native spherical HDL particles or reconstituted apoA-I/phospholipid/cholesterol disks to SR-BI also results in the efflux of unesterified cholesterol from cells to the particles (23) (24) (25) , but the physiological significance of this activity has not yet been determined. ABCA1, a member of the ATP binding cassette (ABC) superfamily of proteins, has a structure strikingly different from that of SR-BI. ABCA1 is a much larger protein (~200 kDa) that contains 12 membrane-spanning helices, two cytoplasmic ATP binding domains, and two large extracellular loops (2, 26, 27) . It mediates the transfer of unesterified cholesterol and phospholipids from cells to lipid-poor apoA-I (28-31), which can subsequently mature into spherical, cholesteryl ester-rich HDL particles (32) (33) (34) (35) These mature HDLs are poor acceptors for ABCA1-mediated cholesterol efflux (36). Mutations in ABCA1 are the underlying cause of Tangier's disease, which is characterized by a virtual absence of spherical, cholesteryl ester-rich HDL particles in the plasma and an accumulation of cholesterol in peripheral macrophages (28, [37] [38] [39] . Mice with targeted homozygous inactivating mutations in the ABCA1 gene exhibit phenotypes similar to those of human Tangier's patients (40) (41) (42) . In contrast, SR-BI deficient mice (homozygous null mutations) have elevated levels of abnormally large lipid-rich HDL particles in their plasma (43) .The differences in the structures of SR-BI and ABCA1 suggest that they employ different mechanisms to transfer lipids between cells and HDL. This is supported by experiments showing that the structural or conformational determinants on apoA-I that are crucial for its interaction with ABCA1 (e.g. apoA-I's C-terminus) appear to differ from those necessary for productive interactions with SR-BI (15, 24, 44) . However, their common abilities to mediate cholesterol efflux from cells led us to probe their activities using small molecules that had previously been shown to inhibit lipid transport activities of either SR-BI -the BLTs (45) -or ABCA1 -glyburide (29, 31, (46) (47) (48) (49) (50) (51) .
Glyburide (also called glybenclamide, Figure 1A ) is a sulfonylurea that has received wide attention in clinical settings as a potent drug for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) (52) . Glyburide binds tightly to and inhibits SUR1 or SUR2, members of the by guest, on October 14, 2017 www.jlr.org
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Small molecule inhibitors of cholesterol efflux page 5 ABC superfamily of proteins that form the sulfonylurea receptor subunit of the ATP-sensitive potassium channel (K ATP channel). SUR1 and -2 are responsible for binding and hydrolysis of ATP and effectively control the closing of the channel and regulating insulin release. The Kd for glyburide binding to SUR1, which apparently involves association with its transmembrane domains, is in the low nanomolar range (reviewed in (53) ). Glyburide also inhibits the activities of other ABC proteins (54) (55) (56) , including ABCA1. Inhibition of ABCA1 by glyburide has been reported to occur in the concentration range of 100-1000 µM (29, 31, (46) (47) (48) (49) (50) (51) .
By using a high throughput chemical library screen, we recently identified five small molecules (BLT-1-5) that in the low nanomolar to micromolar range block lipid transport (selective uptake and efflux from HDL) mediated by the scavenger receptor SR-BI (45).
Unexpectedly, they enhance rather than decrease the apparent affinity of HDL binding to SR-BI.
Here we report that BLT-4 ( Figure 1B ) blocks ABCA1-mediated cholesterol efflux to lipid-free apoA-I. The other BLTs did not inhibit ABCA1 activity. Conversely, glyburide prevented SR-BI-mediated selective lipid uptake from and cholesterol efflux to HDL. Similar to the BLTs, glyburide enhanced the affinity of HDL binding to SR-BI. The concentrations at which glyburide inhibited SR-BI and ABCA1 mediated lipid efflux were similar (IC 50~ of 275-300 µM), as were those for BLT-4, but BLT-4 was the more potent inhibitor (IC 50~ 55-60 µM).
The reciprocal or cross-inhibition of these two lipid transport proteins by BLT-4 and glyburide raises the possibility that there may be similarities in a least one step in mechanisms of SR-BI- 
EXPERIMENTAL PROCEDURES
Stock solutions of BLTs (Chembridge Corp.) and glyburide (Sigma) were prepared in 100% dimethyl sulfoxide (DMSO) and diluted into the assay medium immediately prior to use. Dithiobis (succinimidyl propionate) (DSP, from Pierce Biotechnology, Inc), which contains thiol-sensitive bonds, was dissolved in dimethyl sulfoxide and then diluted to 250 µM with PBS immediately before use.
Lipoproteins and Cells
Human HDL (density of ~1.09-1.16 g/ml) and recombinant lipid-free human apolipoprotein A-I (apoA-I) were isolated and labeled with either (19) , and HEK293-EBNA-T human embryonic kidney cells (27) were maintained in culture as previously described.
All assay media contained 0.5% (v/v) DMSO and 0.5% (w/v) of bovine serum albumin (BSA) (fatty acid free form in efflux assays) and all experiments were conducted at 37°C.
Lipid transport and binding assays
All data presented are representative of results from two or more independent experiments. (19, 45) . Analysis of saturation binding curves was performed using Graphpad Prism3 software from GraphPad Software, Inc, San Diego (CA).
SR-BI:
For some experiments, the values presented were normalized so that the 100% of control represents activity in the absence of compounds. In Crosslinking assay of ApoA-I binding to ABCA1.
The binding assays were conducted as described by Wang et al. (62) with minor modifications.
HEK293-EBNA-T cells were plated as described above in 12-well poly-D-lysine coated plates and three days later were transfected with plasmids when the cells were ~95% confluent as described above. On day 4 the cells were pre-incubated in DMEM (high glucose)/0.2 % (w/v) fatty acid free BSA with the indicated amounts of compounds at 37 o C for 1h prior to the incubation at 37°C for 1 h with 2 µg/ml of 125 I-apoA-I in the presence or absence of a 30-fold excess of unlabeled apoA-I. Cells were then washed, reversibly crosslinked with DSP (2 ml per well) and washed again as previously described (62) . For immunoprecipitation, cell lysates prepared in buffer RI (50 mM Tris, pH 7.6, 150 mM NaCl, 0.25% sodium deoxycholate, 1%
Nonidet P-40, containing protease inhibitors mixture (Roche Molecular Biochemicals, GmbH, Germany) and 1 mM phenylmethylsulfonyl fluoride) were subjected to centrifugation at 1,000xg
in a microcentrifuge for 10 min. The supernatant was collected and precleared with10 µl of GammaBind G Sepharose beads for one hour at room temperature with rotation. Polyclonal anti-ABCA1 antibody (50 µg) directed against the C-terminus of ABCA1 (61) was added to the preabsorbed cell lysates and incubated with rotation at room temperature for 2 hours. Twenty µl of GammaBind G Sepharose beads were then added, and the incubation with rotation was continued at room temp for one hour. The samples were subjected to a brief centrifugation, and the pellets were washed three times with cold buffer RI at room temperature. The bound proteins were eluted from the beads by incubation and boiling in Laemmli sample buffer in the presence of 5% β-mercaptoethanol, which also serves to break the DSP-mediated crosslinks between apoA-I and ABCA1. The eluted proteins were fractionated by 12% SDS-polyacrylamide gel by guest, on October 14, 2017
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electrophoresis and the radioactivity in the dried gels was analyzed using a PhosphorImaging STORM860 system (Molecular Dynamics, Inc., Sunnyvale, CA) and ImageQuant software.
Determination of ABCA1 Expression Levels
To determine the effect of the compounds on the cell surface expression of ABCA1, we employed previously described quantitative assays for cell surface ABCA1 that detects a FLAG tag inserted in the first large extracellular loop of ABCA1 (27) . In brief, HEK293-EBNA-T cells in 24-well plates were transfected with a FLAG-ABCA1 cDNA or empty vectors as described above. The media containing DNA and lipofectamine were removed one day after transfection and one day later the cells were exposed for 5 hours at 37 0 C to assay medium (DMEM-high glucose supplemented with 0.2% fatty acid free BSA, 0.5% DMSO, 25 mM HEPES pH7.4) with or without 150 µM BLT-4 or 500 µM glyburide. The cells were then chilled on ice for 10 minutes and cell surface ABCA1-FLAG expression was measured as described by Fitzgerald et al (27) .
Total cellular ABCA1 expression was measured by immunoblot analysis using a polyclonal antibody as previously described (61 
Synthesis of BLT-4 (1-(2-Methoxy-phenyl)-3-naphthalen-2-yl-urea):
Napthyl isocyanate (Sigma-Aldrich) was dissolved in ethyl acetate and N-methyl-pyrrolidinone (Sigma-Aldrich) then cooled to 0˚C. 2-Anisidine was added drop-wise by syringe over ten minutes. Solid naphtyl isocyanate (1.00g, 5.92 mmol) was dissolved in 45 ml of anhydrous 1:2 N-methyl pyrrolidinone/ethyl acetate (Acros Organics) under a nitrogen atmosphere and cooled to 0˚C. 2-Anisidine (900 µl, 7.32 mmol) was added drop-wise by syringe over ten minutes and the reaction was stirred, first at 0˚C for two hours and then for an additional two hours at room temperature. The reaction was quenched by the addition of 100 ml 0.1N HCl and extracted three cells either with or without apoA-I. Figure 3B shows that the ABCA1-and apoA-I-dependent Figure 3B and (45)).
The shared sensitivities to BLT-4 suggest that there may be similarities in the mechanisms by which BLT-4 inhibited ABCA1-and SR-BI-mediated cellular cholesterol efflux.
The inability of BLT-1, BLT-3 and BLT-5 to inhibit ABCA1 raise the possibility that the mechanisms by which they block SR-BI activity may differ from that of BLT-4, although additional studies will be required to directly address this question. Strikingly, glyburide's effects on SR-BI-mediated efflux were virtually identical to those on ABCA1-mediated efflux. Figure 4B shows that glyburide inhibited SR-BI-mediated and its inhibition of SR-BI-and HDL-dependent cholesterol efflux, shows that the drug is equally potent in inhibiting these cell surface transport proteins.
We also found that lipid-free apoA-I (10 µg protein/ml) was a poor acceptor of SR-BI (24, 57, (64) (65) (66) (67) . We tested the effects of glyburide on these two additional activities of SR-BI. 
Effects of BLT-4 and glyburide on apoA-I binding to ABCA1
The increase in affinity of SR-BI for HDL induced by BLT-4 (see also (45) ) and glyburide prompted us to examine the binding of apoA-I to ABCA1. 
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FOOTNOTES # 1
When ldlA[mSR-BI] or ldlA7 cells were treated with a very high concentration of glyburide, 1 mM, for a total of three hours, we observed morphological changes (e.g., changes in the appearance of the nucleus), and occasionally signs of toxicity as measured by trypan blue exclusion.
# 2
Glyburide at a concentration of 1mM has been reported to prevent specific ABCA1 and apoA-I dependent phospholipid (phosphatidyl choline) efflux from cells, determined as the difference in phospholipid efflux from ABCA1 expressing cells measured in the present and absence of apoA-I in the extracellular medium (29) . We also observed this inhibition at very high doses of glyburide (500 µM and higher). However, we found in our experiments that the glyburide induced decrease in specific apoA-I dependent phospholipid efflux was largely due to an increase in ABCA1-mediated efflux to the apoA-I-free medium rather than a substantial decrease in efflux to apoA-I containing medium (data not shown). presence or absence of a 1:800 dilution of the anti-SR-BI blocking antibody KKB-1 (25) . The 100% of control value represents efflux in the absence of compound (50% of initial cellular radiolabeled cholesterol for efflux to HDL) and the 0% of control value represents efflux in the presence of HDL and the KKB-1 antibody (1:800 dilution) (12% of initial cellular radiolabeled cholesterol). There was no effect of the compounds on efflux to HDL in the presence of KKB-1.
Error bars represent standard deviations from triplicate measurements. 
